Phase 3 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have fully completed a previous clinical study of sotatercept for pulmonary arterial hypertension (a type of high blood pressure affecting the lungs), including all of that study's requirements, and who did not leave that study early
- People who are willing and able to attend all required study visits and follow all study rules and requirements
- People who are able to understand the study and have signed a formal consent form agreeing to take part
Who may not be able to join:
- People who did not take part in a previous sotatercept study for pulmonary arterial hypertension
- People who missed more than 4 doses in a row between the end of the previous study and the start of this one
- People who experienced a serious side effect during a previous sotatercept study that doctors believe was possibly or probably caused by sotatercept, and that side effect is still ongoing
- People who are currently pregnant or breastfeeding
- People who are employed by, or have a close family member directly employed by, the organisation running or sponsoring this study
- People who are currently enrolled in another clinical trial of an experimental treatment (other than a sotatercept study)
- People who are unable to make decisions for themselves or manage their own affairs (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Australian sites
+61295158195
+61731395076
+61870740000
+61361668620
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants Who Experience an Adverse Event (AE); Number of Participants Who Discontinue Study Treatment Due to an AE; Number of Participants with Detectable Anti-Drug Antibodies (ADAs); Laboratory parameters (Hematology): Concentration of Platelets and Hemoglobin; Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT); Change From Baseline in Body Weight; Change From Baseline in Blood Pressure; Change From Baseline in Electrocardiogram (ECG)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.